AI pharmaceutical development concept stocks on the US stock market rose after the market closed, and the US FDA abandoned its animal testing principles

On April 11th, AI pharmaceutical development concept stocks in the US stock market rose after hours, with Certara up over 25%, Schrodinger up over 18%, Recursion Pharmaceuticals up over 21%, Absci Corp up over 17%, and Charles River up over 6%. On the news front, the US Food and Drug Administration (FDA) announced that it will gradually abandon animal testing routes in many drugs such as monoclonal antibodies and instead pursue “more effective human related research methods”.